Beta Bionics, Inc.
https://www.betabionics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Beta Bionics, Inc.
Beta Bionics Secures $100M In Series D Funding To Expand Artificial Pancreas Tech
After receiving US FDA clearance in May, Beta Bionics secured $100m in financing which is expected to be used to commercialize its iLet Bionic Pancreas and “further develop and test the bi-hormonal bionic pancreas.”
Market Intel: Rivalry Among Insulin Pump Makers Heats Up With Expected Launches In 2021
The global insulin pump market is expected to see double-digit growth, reaching $5.1bn in 2024, with product launches expected by Medtronic, Insulet, Tandem and smaller players in 2021.
Tandem Wins FDA Clearance On First Stand-Alone Glycemic Controller
Tandem Diabetes Care received FDA clearance for its Control-IQ technology for use with Tandem's t:slim X2 insulin pump and Dexcom's G6 continuous glucose monitoring system, making it the first hybrid closed-loop system to deliver automatic correction boluses and adjust background insulin levels to help prevent high and low blood sugars.
Market Intel: Bigfoot Biomedical, Beta Bionics Getting Pumped To Introduce Next-Gen Artificial Pancreas
The insulin pump market, which is dominated by four major players, is facing rising competition from smaller, innovative companies. This second part of a two-part series focuses on five emerging companies: Beta Bionics, Bigfoot Biomedical, Diabeloop, EOFlow and Ypsomed.
Company Information
- Industry
- Biotechnology
- Medical Devices
-
Pharmaceuticals
- Drug Delivery
-
Medical Devices
- Monitoring Equipment & Devices
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice